SecBot SecBot
6-K ·Filed Oct 2, 2026

DRUG

BRIGHT MINDS BIOSCIENCES INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed24d 23h ago SEC0001062993-26-005170
Notable filing: 6-K
Actionable Insight • Neutral

No actionable trading signal — this is a standard post-AGM filing with no changes to strategy, capital structure, or operations. Monitor future filings for clinical or financing updates.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+5d
DRUG ▲ +8.48% at T+5d
NEUTRAL call +8.48% · α vs SPY +8.05% · entry $49.79 → $54.01
Next anchor: T+20d in 3d
Latest observation: T+14 +21.48% FF3 residual α
Entry = T+0 close
Oct 2, 2026
via day close
T+1d
-3.09%
call -3.09% · α -3.64%
$48.25
settled 22d ago
T+5d
+8.48%
call +8.48% · α +8.05%
$54.01
settled 18d ago
T+20d
Pending
in 3d
T+60d
Pending
in 2mo

Price Chart

Loading chart...

Executive Summary

Bright Minds Biosciences filed a Form 6-K reporting voting results from its annual general meeting held on March 31, 2026. All six director nominees were elected with strong support (89.76% to 100% votes for), and De Visser Gray LLP was reappointed as auditor with 99.94% approval. The filing is a routine procedural update with no material financial or operational impact.

Key Facts

  • Annual general meeting held March 31, 2026; 7,877,637 common shares voted (80.49% of outstanding).
  • All six director nominees elected with votes for ranging from 89.76% (Nils Bottler) to 100% (Steve Farr).
  • De Visser Gray LLP reappointed as auditor with 99.94% votes for.
  • Form 6-K filed October 2, 2026, incorporating the voting results by reference into existing F-3 registration statements.

Financial Impact

No financial impact; routine governance filing.

Risk Factors

  • No material risks identified from this filing.

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001062993-26-005170
Document: form6k.htm0001062993-26-005170
Document: 0001062993-26-005170-index-headers.html0001062993-26-005170
Document: 0001062993-26-005170-index.html0001062993-26-005170
Document: 0001062993-26-005170.txt0001062993-26-005170
3 reports for DRUG
Performance horizon
Filters
Rows
Reports for DRUG — sortable, filterable
TypeNow
Oct 2, 2026
24d ago
6-K
NEUTRAL ★ 2/10
$49.79awaiting T+20—$54.02 (+8.50%)
Jun 3, 2026
20w ago
6-K
NEUTRAL ★ 2/10
$74.42 $67.60▼ −9.16%▼ −8.16%$54.02 (−27.41%)
Jun 2, 2026
21w ago
6-K
NEUTRAL ★ 2/10
$76.78 $66.54▼ −13.34%▼ −11.77%$54.02 (−29.64%)
Showing 3 of 3

US Market Status

Market Closed — Opens Wed (16h 24m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 2, 2026